MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. - Wikidata - wikimedia - TriplyDB

MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.

MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.

http://www.wikidata.org/entity/Q34113855

about

Implication of IRF4 aberrant gene expression in the acute leukemias of childhood Direct inhibition of the NOTCH transcription factor complex The rate of spontaneous mutations in human myeloid cells Proteomic and genetic approaches identify Syk as an AML target.Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells.Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.The Biology and Targeting of FLT3 in Pediatric Leukemia.Role of misfolded N-CoR mediated transcriptional deregulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype.Development of a multi-step leukemogenesis model of MLL-rearranged leukemia using humanized mice FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm Optical imaging in vivo with a focus on paediatric disease: technical progress, current preclinical and clinical applications and future perspectives Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner.Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.The molecular basis of myeloid malignancies.An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.Transcriptome sequencing reveals CHD1 as a novel fusion partner of RUNX1 in acute myeloid leukemia with t(5;21)(q21;q22).An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction Digitalization of a non-irradiated acute myeloid leukemia model.Molecular genetics of B-precursor acute lymphoblastic leukemia Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.Cell of origin determines clinically relevant subtypes of MLL-rearranged AML Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles.Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.Therapeutic targeting of MLL.Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.Molecular pathology of mixed-lineage leukemia.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.Mechanisms of mixed-lineage leukemia.Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD).

P2860

Q21090722-DAEDE9BB-5263-4B6B-9015-E7BBAF9DB90A Q24634015-502B5518-9C57-4E26-AB1E-7490760DEB15 Q28645706-7E62807F-4E0E-4E33-8CD7-FC47D3B61529 Q33577098-44B08513-1B8C-4B2B-ABE7-324A08F88093 Q33595654-0E933646-B20F-48EC-8B58-0871384E218D Q33666543-73787516-30D0-41F2-B68E-847E2D36D1A1 Q33767026-FF9FF194-F147-4ED2-AA48-731B1456E463 Q34229555-48A75C21-8CA4-4328-A610-7698AD9D00C2 Q34238553-1AC9FE15-39B8-49F8-B1EE-501DE87C65EA Q34321077-1C9E8451-FD0A-4439-9B35-0999684F0900 Q34408941-392F4DB2-6282-4927-B148-CC5EF756D2F8 Q34544842-5E8D686B-616F-46A9-AE2C-29E3DA1A76E8 Q34718209-A0D77A48-D6A3-4042-8F46-63ACF12BBAF8 Q34973744-DA843814-DCFA-4202-986D-A14302A9E78A Q35018755-9FE7C60A-2D12-4135-97E4-185830DA5EA8 Q35103708-CE0ABEC5-82F5-46E6-B8CF-B4422EF1EA53 Q35237394-F15D7148-9999-4934-BB50-78A35336D9CF Q35553586-5C6C4E96-7975-46B4-A4EF-C0F27F425653 Q35569079-BD909A6F-FE1A-4477-A24F-F7B5750D05A7 Q35685296-D86A9BC7-D769-44C9-AB4B-712570E04385 Q35800581-BFF36DB5-92FE-4A05-8D62-F042D742FF71 Q35866682-A352F498-DCF2-4C40-852C-15C2E6876FAB Q36036310-16865F97-B7A8-4A60-A302-BD95873C63C8 Q36120326-7C6F1581-8531-43BF-B713-6873AE3317C7 Q36290242-4845CF08-FD4B-4776-93F4-AEF8826A3392 Q36318153-441031B9-7382-4FCA-A7F4-E7CFBB025179 Q36409664-234D37EA-3945-4599-BB10-B69D86815482 Q36455309-ACAF764B-4AAF-40F2-A520-D655D887394F Q36793806-430BC684-FAC5-4145-AC80-D9996A84B2C2 Q37081990-0FA3AD02-8A6D-4CAD-B7CC-B366C72E6229 Q37234595-C564F485-D618-493E-BE80-52C8431E4767 Q37295285-4EA91317-EA0A-4BC9-BEA8-68337CA4420F Q37330859-9C3A81B8-33A2-4727-BB88-C11D612A8C58 Q37460343-B06ECF66-8A2C-4F7D-997E-8960FA58D683 Q37565082-651A7A17-7D4C-4DBA-801E-CFC811EDB499 Q37620396-21FB803F-EE88-4396-A207-629BF57441C3 Q37633585-C0FDE728-0436-44AF-99C5-BABD6FB90B62 Q37874929-83BA3660-A23C-4DFB-98E5-5E3C1CE13D58 Q38190545-35E87436-CADC-45E5-966B-0421758FEF3B Q38641382-5FD36F67-E969-4459-B867-177EF8EBDF5D

P2860

MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.

http://www.wikidata.org/entity/Q34113855

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

MLL-AF9 and FLT3 cooperation i ...... rapid therapeutic assessment.

@ast

MLL-AF9 and FLT3 cooperation i ...... rapid therapeutic assessment.

@en

MLL-AF9 and FLT3 cooperation i ...... rapid therapeutic assessment.

@nl

type

label

MLL-AF9 and FLT3 cooperation i ...... rapid therapeutic assessment.

@ast

MLL-AF9 and FLT3 cooperation i ...... rapid therapeutic assessment.

@en

MLL-AF9 and FLT3 cooperation i ...... rapid therapeutic assessment.

@nl

prefLabel

MLL-AF9 and FLT3 cooperation i ...... rapid therapeutic assessment.

@ast

MLL-AF9 and FLT3 cooperation i ...... rapid therapeutic assessment.

@en

MLL-AF9 and FLT3 cooperation i ...... rapid therapeutic assessment.

@nl

P1433

Q34113855-066C9A18-43BE-4763-B8B7-A1A9EA4B9AB3

P1476

Q34113855-939703E0-4952-4DC0-BE33-6B171CA4446A

P2093

Q34113855-398C301B-7B7C-4E8E-94CB-BBF7A3307FF3

Q34113855-64113368-EFF0-4222-ADB1-2DCE24EA1277

Q34113855-7C4C9B14-8459-4B88-A902-1DA5D06B2EBC

Q34113855-A1C3792B-7AD8-4ECC-9BB6-A1BE1F1C06D9

Q34113855-A6D2DC09-01F6-4B30-B5B0-227EC4730D6C

Q34113855-DE50686A-ADB4-4F3D-9F87-822507C0E705

Q34113855-E06E3798-B60B-483A-AB37-76500CC24154

P2860

Q34113855-01F32AE5-3C12-4F8C-861B-3ED2B6F4D342

Q34113855-09516AB1-C432-48BE-81D7-3B12174E0E0B

Q34113855-0B771DC6-B49E-453B-80DC-AFD843358E75

Q34113855-169D3010-E60D-4607-9D92-BBB28BAC9ADC

Q34113855-213BDB6D-76B5-4E79-BF82-5BAF12936E10

Q34113855-29A2199F-56C5-43AF-935B-698B42135928

Q34113855-2BEEB9B0-6207-4908-9669-9720B9F125FF

Q34113855-3D899BA0-EAF1-4312-BBE7-911A4440AE84

Q34113855-3D933E23-1C04-4C6C-AFBC-04136E222532

Q34113855-43218A2E-962A-4B79-A771-94106777B3AA

P2888

Q34113855-5D27D70A-DDB3-4466-911B-FC35340DD643

P304

Q34113855-A0B071BB-9811-4D6A-A85D-0BBA92F15625

P31

Q34113855-9FC98027-C768-44C1-86A2-01C7314C7FA0

P356

Q34113855-1316EC38-9973-46E5-B964-4120C0155124

P433

Q34113855-403C7F3C-DABE-444B-AD81-FED69221E47E

P478

Q34113855-1C014C8E-0D94-417E-9CEE-28D2D6668067

P50

Q34113855-956E05B5-7C05-49AF-A157-74AEA163750C

P577

Q34113855-39527C2F-E6DF-450C-84DB-92888F0A19C5

P5875

Q34113855-70916C6F-C950-49EC-8FC8-FA8AC5B787FC

P6179

Q34113855-1B84A76D-C71B-4CC2-862F-06A792999CBF

P698

Q34113855-661B9C2C-44BF-4DF3-9EAC-CF0869F4BF9A

P921

Q34113855-3020792B-19BA-4750-BD74-16AAD8D9CC9D

P932

Q34113855-230954E8-5DE6-4744-804E-92046D90878B

P356

P1433

P1476

MLL-AF9 and FLT3 cooperation i ...... r rapid therapeutic assessment

@en

P2093

A V Krivtsov

http://www.w3.org/2001/XMLSchema#string

J Agarwal

http://www.w3.org/2001/XMLSchema#string

M C Stubbs

http://www.w3.org/2001/XMLSchema#string

R D Wright

http://www.w3.org/2001/XMLSchema#string

S A Armstrong

http://www.w3.org/2001/XMLSchema#string

Y M Kim

http://www.w3.org/2001/XMLSchema#string

Z Feng

http://www.w3.org/2001/XMLSchema#string

P2860

The role of FLT3 in haematopoietic malignancies

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

An Mll-dependent Hox program drives hematopoietic progenitor expansion

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

A clonogenic common myeloid progenitor that gives rise to all myeloid lineages

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Mll rearrangements in haematological malignancies: lessons from clinical and biological studies.

Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease.

Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.

P2888

P304

66-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2404951

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5988133

http://www.w3.org/2001/XMLSchema#string

P6179

1029740613

http://www.w3.org/2001/XMLSchema#string

P698

17851551

http://www.w3.org/2001/XMLSchema#string

P921

P932

2936245

http://www.w3.org/2001/XMLSchema#string